Wall Street brokerages expect that Ionis Pharmaceuticals Inc (NASDAQ:IONS) will report $159.81 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Ionis Pharmaceuticals’ earnings, with estimates ranging from $89.47 million to $260.20 million. Ionis Pharmaceuticals reported sales of $110.30 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 44.9%. The firm is expected to announce its next quarterly earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Ionis Pharmaceuticals will report full year sales of $159.81 million for the current fiscal year, with estimates ranging from $370.33 million to $716.00 million. For the next fiscal year, analysts expect that the business will post sales of $664.69 million per share, with estimates ranging from $404.19 million to $1.08 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Ionis Pharmaceuticals.
Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Tuesday, February 27th. The company reported $0.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.10. Ionis Pharmaceuticals had a negative return on equity of 1.94% and a negative net margin of 1.18%. The business had revenue of $172.00 million for the quarter, compared to analysts’ expectations of $126.38 million. During the same period in the prior year, the business posted $0.33 earnings per share. The firm’s revenue was up 7.5% on a year-over-year basis.
In other news, SVP Elizabeth L. Hougen sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $52.55, for a total transaction of $262,750.00. Following the transaction, the senior vice president now directly owns 15,392 shares of the company’s stock, valued at $808,849.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joseph Klein III sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $51.69, for a total value of $155,070.00. Following the transaction, the director now directly owns 12,939 shares in the company, valued at $668,816.91. The disclosure for this sale can be found here. Over the last three months, insiders sold 113,635 shares of company stock worth $5,876,141. Insiders own 2.13% of the company’s stock.
Several large investors have recently modified their holdings of the company. Xact Kapitalforvaltning AB acquired a new position in shares of Ionis Pharmaceuticals during the fourth quarter worth approximately $599,000. Iguana Healthcare Management LLC raised its position in shares of Ionis Pharmaceuticals by 166.7% during the fourth quarter. Iguana Healthcare Management LLC now owns 40,000 shares of the company’s stock worth $2,012,000 after purchasing an additional 25,000 shares during the period. LPL Financial LLC raised its position in shares of Ionis Pharmaceuticals by 14.6% during the fourth quarter. LPL Financial LLC now owns 50,677 shares of the company’s stock worth $2,549,000 after purchasing an additional 6,465 shares during the period. Millennium Management LLC raised its position in shares of Ionis Pharmaceuticals by 1.5% during the fourth quarter. Millennium Management LLC now owns 195,917 shares of the company’s stock worth $9,855,000 after purchasing an additional 2,874 shares during the period. Finally, Teachers Advisors LLC raised its position in shares of Ionis Pharmaceuticals by 1.4% during the fourth quarter. Teachers Advisors LLC now owns 134,007 shares of the company’s stock worth $6,741,000 after purchasing an additional 1,913 shares during the period. 90.95% of the stock is currently owned by institutional investors.
Shares of Ionis Pharmaceuticals (NASDAQ:IONS) opened at $54.78 on Tuesday. Ionis Pharmaceuticals has a twelve month low of $37.26 and a twelve month high of $65.51. The company has a market capitalization of $6,840.00, a P/E ratio of 68.48 and a beta of 2.43. The company has a quick ratio of 5.15, a current ratio of 5.20 and a debt-to-equity ratio of 1.45.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.